title: Anti-inflammatory therapeutics for the treatment of atherosclerosis.
abstract: Atherosclerosis is the primary cause of heart disease and stroke and is thus the underlying pathology of the leading causes of death in the western world. Although risk can be reduced by lowering lipid levels, the equally important contribution of inflammation to the development of cardiovascular disease is not adequately addressed by existing therapies. Here, we summarize the evidence supporting a role for inflammation in the pathogenesis of atherosclerosis, discuss agents that are currently in the clinic and provide a perspective on the challenges faced in the development of drugs that target vascular inflammation.
authors.affiliation: Gladstone Institute of Cardiovascular Disease, 1650 Owens Street #149, San Francisco, California 94158, USA. icharo@gladstone.ucsf.edu
authors.forename: Israel F
authors.initials: IF
authors.lastname: Charo
authors.forename: Rebecca
authors.initials: R
authors.lastname: Taub
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000893:Anti-Inflammatory Agents